Graphene nanoribbons - Theragnostic Technologies

Drug Profile

Graphene nanoribbons - Theragnostic Technologies

Alternative Names: O-GNR-PEG-DSPE

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Theragnostic Technologies
  • Class Antineoplastics; Antivirals; Imaging agents
  • Mechanism of Action Diagnostic imaging enhancers; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cervical cancer; Head and neck cancer; Herpesvirus infections

Most Recent Events

  • 20 Jul 2016 Preclinical trials in Herpesvirus infections in USA (Parenteral)
  • 20 Jul 2016 Preclinical trials in Head and neck cancer in USA (Parenteral)
  • 20 Jul 2016 Preclinical trials in Cervical cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top